Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...
New insights from Gordon Fraser spotlight a Triple Lipid Complex that supports skin barrier function, hydration, and ...
Rocheleau previously served as Vice President of Express Brokerage Operations at FedEx and will lead operational ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...
Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment ...
Leaders of an effort to finance a $16.7 million renovation of Joplin’s Memorial Hall told residents during a Monday night presentation that they were hoping to receive approval of a memorandum of ...
Smoking is a major cause of morbidity and mortality, resulting in an increased risk of cardiovascular, respiratory, inflammatory, and degenerative diseases. In this review, we highlight the complex ...
Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results